AbbVie moved to acquire Apogee Therapeutics after years of discussions, setting up a $10.9 billion deal structure described in coverage of the transaction. The report also notes additional regulatory and market context, including a UK drug pricing pilot. For Apogee, the takeover ends a long search for scale and late-stage development resources. For AbbVie, adding Apogee’s pipeline and platform capabilities supports continued portfolio building across immunology and other high-value disease areas. The size and structure of the proposed consideration highlight how large-cap drugmakers keep funding capacity for targeted biotech bets as competition for late-stage assets intensifies.